Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation.
Authors | |
Keywords | |
Abstract | PURPOSE: Recurrently mutated genes in myelodysplastic syndrome (MDS) are pathogenic drivers and powerfully associated with clinical phenotype and prognosis. Whether these types of mutations predict outcome after allogeneic hematopoietic stem-cell transplantation (HSCT) in patients with MDS is not known. PATIENTS AND METHODS: We used massively parallel sequencing to examine tumor samples collected from 87 patients with MDS before HSCT for coding mutations in 40 recurrently mutated MDS genes. RESULTS: Mutations were identified in 92% of patients, most frequently in the ASXL1 (29%), TP53 (21%), DNMT3A (18%), and RUNX1 (16%) genes. In univariable analyses, only TP53 mutations were associated with shorter overall (OS; hazard ratio [HR], 3.74; P CONCLUSION: Mutations in TP53, TET2, or DNMT3A identify patients with MDS with shorter OS after HSCT. |
Year of Publication | 2014
|
Journal | J Clin Oncol
|
Volume | 32
|
Issue | 25
|
Pages | 2691-8
|
Date Published | 2014 Sep 01
|
ISSN | 1527-7755
|
URL | |
DOI | 10.1200/JCO.2013.52.3381
|
PubMed ID | 25092778
|
PubMed Central ID | PMC4207878
|
Links | |
Grant list | R01 HL082945 / HL / NHLBI NIH HHS / United States
T32 CA009172 / CA / NCI NIH HHS / United States
P30 CA023100 / CA / NCI NIH HHS / United States
K08 DK091360 / DK / NIDDK NIH HHS / United States
5K08DK091360 / DK / NIDDK NIH HHS / United States
R01 CA183559 / CA / NCI NIH HHS / United States
R01HL082945 / HL / NHLBI NIH HHS / United States
|